Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Discussion
Amgen reported findings from a post-hoc analysis of the pivotal Phase 3 ASPIRE clinical trial, highlighting the continued benefits of carfilzomib (Kyprolis), a second-generation proteasome inhibitor, plus a standard…
Discussion
Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care…
Discussion
Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple…
Discussion
The Multiple Myeloma Research Foundation (MMRF) has announced that its founder, Kathy Giusti, has been appointed faculty co-chair of the Harvard Business School (HBS)…
Discussion
Researchers at the University of Louisville and collaborators from Japan and Austria have identified a protein called AF1q whose expression may predict the development of an…
Discussion
Researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) have showed that maintenance lenalidomide (marketed as Revlimid) following autologous hematopoietic stem cell (HSC) transplant improves…
